Posted on

The MPC Research File: Every Published Study on Muscadine, Accurately Scoped

Hands holding Noble muscadines.

If you’re making a sourcing decision about muscadine, you need to know exactly what the published research shows — not a summary, not a highlight reel. Every study specifically on muscadine relevant to supplement formulation, with design, population, and findings clearly stated.

If you’re a formulator evaluating muscadine as an ingredient, this is your research starting point. Share it with your R&D team. Let your regulatory counsel work from these citations. Build your formula on what the research supports.

Study 1: Banini et al. — Metabolic Markers in T2D Subjects

Banini AE et al. Nutrition 2006; 22(11–12):1137–1145. North Carolina State University.
Study typeDietary intervention. Non-randomized. 28 days.
PopulationType 2 diabetic subjects (assigned to muscadine juice, wine, or dealcoholized wine) and non-diabetic subjects (juice only)
Intervention150 mL/day of muscadine grape juice, wine, or dealcoholized wine with meals
Key findingDiabetics given muscadine wine and dealcoholized wine showed lower blood glucose, insulin, and glycated hemoglobin compared to diabetics given juice. Significant improvement in fasting insulin only in the dealcoholized wine group.
LimitsNon-diabetic group received juice only — no comparison arm across product types. No placebo control. Beverage forms only — not encapsulated extract. Cannot generalize findings to healthy populations.

What this gives a formulator: peer-reviewed human research on muscadine and metabolic markers in a population where those markers matter. What it doesn’t give: evidence of metabolic benefit in healthy adults or in capsule supplement form.

Study 2: Mellen et al. — Cardiovascular Markers in Cardiac Risk Population

Mellen PB et al. J Am Coll Nutr 2010; 29(5):469–475. Hypertension Center of Excellence, Hattiesburg Clinic.
Study typeRandomized, double-blind, placebo-controlled crossover trial. 4 weeks each, 4-week washout.
Population50 adults with coronary disease or ≥1 cardiac risk factor
InterventionMuscadine grape seed supplement at 1,300 mg/day vs. placebo
Key findingPrimary endpoint (FMD): not statistically significant (p=0.06). Secondary finding: significant increase in resting brachial diameter (p=0.002) — clinical significance not yet established. No significant change in inflammation, lipid peroxidation, or antioxidant capacity biomarkers.
LimitsPrimary endpoint not met. Secondary finding of unclear clinical significance. Authors called for more research.

What this gives a formulator: one of the most rigorous study designs in nutritional science, applied specifically to muscadine grape seed in a cardiovascular risk population. That research credential is real, even though the primary endpoint wasn’t met. What it doesn’t give: evidence of cardiovascular benefit.

Study 3: Ghanim et al. — Oxidative Stress in a Meal Challenge

Ghanim H et al. J Clin Endocrinol Metab 2011; 96(5):1409–1414. State University of New York at Buffalo.
Study typeHuman meal challenge trial. Randomized crossover with placebo. 10 subjects.
Population10 healthy adults. High-fat, high-carbohydrate meal challenge.
InterventionCombination supplement containing resveratrol AND muscadine grape polyphenols — not muscadine alone
Key findingThe combination supplement reduced meal-induced oxidative and inflammatory stress markers and stimulated Nrf-2 antioxidant transcription factor activity compared to placebo.*
LimitsCombination supplement — muscadine’s specific contribution cannot be isolated from resveratrol’s. Small study (n=10). Meal challenge context only, not general supplementation.

What this gives a formulator: peer-reviewed human evidence that a resveratrol-and-muscadine polyphenol combination affected oxidative stress markers during a meal challenge, including Nrf-2 activation. What it doesn’t give: evidence that muscadine alone produces these effects, or that the same effects occur in a general supplementation context.

Study 4: Patil et al. — Cardiac Damage in an Animal Hypertension Model

Patil PD et al. Antioxidants 2022; 11(10):2026. Wake Forest University School of Medicine.
Study typeAnimal model study. Rodent (Sprague Dawley rats). 4 weeks.
PopulationMale rats with angiotensin II-induced hypertension
InterventionMuscadine grape skin/seed extract supplement vs. control
Key findingMGES did not affect blood pressure but attenuated hypertension-induced diastolic dysfunction markers (E/e’ ratio) in the animal model. Researchers observed reductions in oxidative stress markers and macrophage infiltration in cardiac tissue.
LimitsAnimal model only — findings in rats do not directly establish human outcomes. Results are mechanistic and hypothesis-generating, not clinically conclusive.

What this provides a formulator: peer-reviewed research from Wake Forest University School of Medicine on a muscadine skin/seed extract and cardiovascular-relevant endpoints in an animal model. What it doesn’t provide: human clinical evidence.

What the Full Research File Means for Your Formula

Four published studies specifically on muscadine. Two human trials, one human meal challenge using a combination supplement, and one animal model. That’s a meaningful research base for a botanical ingredient — and we’re presenting every limitation alongside every finding so your team can evaluate them accurately.

Here’s what you can build on, honestly:

  • Muscadine has been studied in peer-reviewed human research in metabolic and cardiovascular contexts — areas where formulators face the most scrutiny over ingredient credentials
  • The research spans three institutions: North Carolina State University, Hattiesburg Clinic, and Wake Forest University School of Medicine.
  • The compound profile studied — skin, seed, juice, and combination forms — maps directly to the ingredient forms MPC supplies.
  • No study produced a definitive positive primary outcome in a healthy general population, so your label claims need to be based on structure/function language, with guidance from regulatory counsel
  • Your regulatory counsel and R&D team are best positioned to determine how this research base supports your specific formula and claims.

Paulk Vineyards grows muscadines. MPC processes everything on-site. 800+ acres in Wray, Georgia. Seventh generation on the farm, fourth with muscadines. We can provide full documentation for every study cited here.

Request the full research file or a sample at muscadineproducts.com.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Research references cited include human dietary intervention studies, a human meal-challenge trial using a combination supplement, and an animal model study. Findings from each study reflect what was observed in the specific study population and design described; they do not establish that any MPC muscadine ingredient product produces the same effects. The Ghanim et al. (2011) study used a combination of resveratrol and muscadine polyphenols; muscadine’s independent contribution cannot be isolated from that data. The Patil et al. (2022) study was conducted in an animal model; findings do not directly establish human outcomes. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products.  

Muscadine Products Corporation  •  Wray, Georgia  •  muscadineproducts.com
Posted on

Muscadine and Cardiovascular Health: What the Research Shows and Why It Matters for Your Formula

Wray, Georgia, evening light over the lake. Some weeks get away from you. The vine keeps growing regardless.

If you’re developing a cardiovascular supplement, you already know the challenge: the category is competitive, consumers are sophisticated, and retailers and practitioners have seen enough weak science to ask tough questions. You need an ingredient with a solid research story behind it — not a mechanistic rationale dressed up as clinical evidence.

Muscadine is that ingredient. It has a documented phytochemical profile featuring compounds that appear throughout the polyphenol-vascular research literature, a peer-reviewed human trial specifically on muscadine grape seed and cardiovascular markers, and a fully traceable domestic estate supply chain. That’s a combination most cardiovascular botanical ingredients on the market can’t match.

Here’s what that research shows — and how to use it honestly in your formula.

The Problem Formulators Bring to Us

The formulators who come to us are looking for a cardiovascular ingredient that does three things: connects to published research, has a traceable supply chain, and gives their brand a story that holds up when a buyer or practitioner asks the right questions.

Muscadine addresses all three. The phytochemical profile is documented. A human trial exists, and we’ll tell you exactly what it found. Paulk Vineyards grows muscadines on 800+ acres in Wray, Georgia — seventh generation on the farm, fourth with muscadines — with MPC processing everything on-site. One supply chain. No brokers.

That gap is where brands get caught — in a retailer’s science review, a practitioner’s due diligence, or a direct question from a consumer who reads labels. The brands that hold up in this category long term are those that built on honest research foundations from the start.

The Research Context Muscadine Brings to the Table

Muscadine’s phytochemical profile — anthocyanins, OPCs, ellagic acid, and resveratrol — places it squarely within the class of compounds most extensively studied for vascular health. A 2022 systematic review published in Nutrients (Grosso et al.) examined human studies on dietary polyphenol consumption and its associations with vascular health, blood pressure, and hypertension.

The review found that some polyphenol-rich food categories — particularly those rich in anthocyanins — show evidence of an association with blood pressure outcomes, and that anthocyanin intake was consistently associated with reduced hypertension risk across prospective cohort data — an epidemiological finding, not a clinical claim about any specific supplement product.* The proposed mechanisms include nitric oxide bioavailability, support for endothelial function, and antioxidant activity in vascular tissue.

Muscadine contains all of those compound classes. The review examined dietary polyphenols broadly, not muscadine specifically — and that distinction matters for how you use this research in a label-claim context. But it establishes a meaningful scientific framework for why muscadine’s profile warrants a formulator’s attention in this category.

(See the full disclaimer at the end of this post regarding the scope of these findings.) The distinction matters. A formulator should not cite this review as clinical evidence that a muscadine supplement supports cardiovascular health. It provides a research framework — both mechanistic and epidemiological — showing that the class of compounds found in muscadine has been studied in relation to vascular health. That’s a legitimate research context. It is not a finished clinical claim.

The Muscadine Human Trial: Honest, Peer-Reviewed, and Worth Knowing

The Mellen et al. study (Journal of the American College of Nutrition, 2010) is the most directly relevant published human trial on muscadine and cardiovascular markers. It’s a randomized, double-blind, placebo-controlled crossover trial — one of the most rigorous study designs in nutritional science. The trial included 50 adults with coronary disease or at least one cardiac risk factor. Muscadine grape seed supplementation was 1,300 mg daily for four weeks.

We’re going deeper into that study next week: the full methodology, what the secondary finding does and doesn’t mean, and how a formulator should approach positioning an ingredient whose best clinical trial produced a null primary result.

What Muscadine Gives a Cardiovascular Formulator

We understand the commercial pull of this category — cardiovascular is one of the largest supplement markets, and consumers are actively seeking products. The challenge is building something you can stand behind when the questions get hard. An honest cardiovascular formula story looks like this:

  • A phytochemical profile — anthocyanins, OPCs, ellagic acid, and resveratrol — with documented presence in the polyphenol-vascular research literature
  • A peer-reviewed, randomized, placebo-controlled human trial focused specifically on muscadine grape seed — with outcomes accurately disclosed, including the null primary endpoint
  • A fully traceable domestic estate supply chain: Paulk Vineyards grows, MPC processes, no brokers, and full lot documentation
  • An ingredient partner who will provide you with the research, the documentation, and an honest account of what it shows — so your regulatory team can build claims that hold up

Request a sample, review the Mellen study documentation, or schedule a sourcing call at muscadineproducts.com.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The Grosso et al. (2022) review examined dietary polyphenol consumption and vascular health broadly across human studies; findings reflect associations observed in the reviewed literature and do not constitute evidence that any specific muscadine ingredient product produces cardiovascular health benefits. The Mellen et al. (2010) study examined muscadine grape seed supplementation in a cardiovascular risk population; the primary outcome was not statistically significant. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products.   Muscadine Products Corporation  •  Wray, Georgia  •  muscadineproducts.com
Posted on

Where We Left Off: Closing Out Antioxidants and Opening Cardiovascular Health

Wray, Georgia, evening light over the lake. Some weeks get away from you. The vine keeps growing regardless.

We missed a couple of weeks in this series. My son got married, and that took priority over the publishing calendar — no apology needed for that trade, and I’d make it again.

Rather than backfill two posts that have already lost their moment, we’re picking up the series where it matters most: closing out June’s antioxidant theme with the piece that ties it together and opening July with what’s next. If you want the OPC and ellagic acid stack content or the deeper estate-sourcing piece we’d originally planned for mid-June, reach out — we’re happy to send that material directly.

Closing Out Antioxidants: The Sourcing Argument

Everything we covered this month came back to the same point: a defensible antioxidant formula needs a mechanistic story, not just an ORAC number. Ellagic acid, OPCs, resveratrol, and anthocyanins — the muscadine phytochemical profile — connect to documented oxidative stress pathways in published research, including UV-relevant mechanisms studied in human skin cell models.

The sourcing side of that story is just as important as the science. Muscadine Seed Extract and Extract Powder come from Paulk Vineyards, the growing operation — 800+ acres in Wray, Georgia, seventh generation on the farm, fourth generation with muscadines. Muscadine Products Corporation processes everything on-site. No brokers between the vine and the ingredient lot. When a formulator builds a claim on a specific mechanism and a traceable source, that claim holds up in a way a generic antioxidant blend usually doesn’t.

That’s where we left it.

Opening Cardiovascular: Starting With Honest Research

Cardiovascular health is one of the most scrutinized categories in the supplement industry, and it deserves that scrutiny. Claims in this space are held to the real clinical literature more often than in almost any other category because the stakes for consumers are higher.

The most directly relevant published human research on muscadine and cardiovascular outcomes is the Mellen et al. study (Journal of the American College of Nutrition, 2010). It’s worth knowing exactly what that study found before we go further into July, because we’re not going to build this month’s content on a study we haven’t represented accurately.

Here’s the honest summary: 50 adults with coronary disease or at least one cardiac risk factor received 1,300 mg of muscadine grape seed supplement daily or placebo for four weeks each in a randomized, double-blind, crossover design. The primary outcome — flow-mediated dilation, a measure of endothelial function — did not show a statistically significant improvement. There was a significant increase in resting brachial artery diameter with muscadine grape seed supplementation, but the study authors explicitly stated that the clinical significance of this finding has not yet been established.

  • Primary endpoint (FMD): not statistically significant
  • Secondary finding (resting brachial diameter): statistically significant increase; clinical significance not established
  • No significant changes in biomarkers of inflammation, lipid peroxidation, or antioxidant capacity
  • Study authors’ conclusion: more research is needed to fully characterize the vascular effects of muscadine and other grape-derived supplements and to determine whether those effects translate into clinical benefit

We’re telling you this upfront because it’s the responsible way to open a month built around cardiovascular claims — and because a cardiovascular ingredient story built on a misread study is the kind of thing that falls apart the moment a retailer’s science team or a practitioner asks a follow-up question. The study does not support a cardiovascular benefit claim for muscadine grape seed supplementation. (These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.) What it does establish is that muscadine grape seed has been studied in a real, peer-reviewed, randomized trial in a cardiovascular risk population. That puts it in different territory than most botanical ingredients marketed for heart health. Most of those have no human trial data to back them up at all.

Over the next few weeks, we’ll delve deeper into that study, the broader polyphenol-vascular research landscape, and how a formulator should approach positioning an ingredient with this kind of research profile — real, peer-reviewed, and not yet conclusive.

If you want the full Mellen study citation and methodology to start that conversation with your R&D team, reach out at muscadineproducts.com.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The Mellen et al. (2010) study examined muscadine grape seed supplementation in subjects with coronary disease or cardiac risk factors; the primary outcome measure did not reach statistical significance, and the clinical significance of the secondary finding has not been established. This research does not constitute evidence of a cardiovascular health benefit. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products.   Muscadine Products Corporation  •  Wray, Georgia  •  muscadineproducts.com

Posted on

What the Banini Study Actually Shows — and What It Doesn’t

muscaidne vine close up in late spring

Last week, we made a commitment: to tell you what the research on muscadine actually shows, including where it stops. This week, we’re following through.

The Banini study is the most directly relevant published human trial on muscadine and metabolic markers. Here’s exactly what it was, what it found, and where its limits lie.

The Study at a Glance

Banini AE, Boyd LC, Allen JC, Allen HG, and Sauls DL. “Muscadine grape products intake, diet and blood constituents of non-diabetic and type 2 diabetic subjects.” Nutrition, 2006; 22(11–12):1137–1145. North Carolina State University.

ElementDetail
StudyBanini AE et al., Nutrition 2006; 22(11–12):1137–1145
InstitutionNorth Carolina State University, Raleigh, NC
DesignNon-randomized, non-blinded dietary intervention; 28 days
PopulationType 2 diabetic subjects (assigned to MJ, MW, or Dz-W) and non-diabetic subjects (juice only)
Intervention150 mL/day of muscadine grape juice (MJ), muscadine grape wine (MW), or dealcoholized muscadine grape wine (Dz-W) with meals
Primary outcomesGlycemic indices, blood glucose, insulin, glycated hemoglobin (HbA1c), lipid profile, blood constituents
Key findingsDiabetics given MW and Dz-W showed lower blood glucose, insulin, and HbA1c vs. diabetics given MJ. Dz-W group: fasting blood insulin reduced; glucose:insulin ratio improved from 8.5 to 13.1. MJ and MW did not differ in fasting glucose, insulin, or HbA1c in the non-diabetic group.
Study limitationNon-diabetic group received juice only — no wine or Dz-W arm. No placebo control. Cannot compare non-diabetic outcomes to diabetic outcomes across product types.

What It Found

The most meaningful findings came from Type 2 diabetic subjects assigned to muscadine wine and dealcoholized muscadine wine. Compared with diabetics given muscadine juice, those groups had lower blood glucose, insulin, and glycated hemoglobin levels over the 28-day period.

The dealcoholized wine group — the arm most relevant to a supplement context, since alcohol is removed — showed a specific improvement in fasting blood insulin levels. The fasting blood glucose-to-insulin ratio rose from 8.5 to 13.1 over the intervention period. The researchers noted that a ratio below 7 is considered predictive of insulin resistance; the published data showed movement away from that threshold in the T2D group over 28 days.

These are real findings from a real peer-reviewed study in a population where metabolic markers matter most.

What It Doesn’t Show

Here is where we’re going to be direct, because this is where ingredient marketing most often goes wrong.

The non-diabetic subjects in this study received only muscadine juice. There was no wine or dealcoholized wine arm for healthy subjects, and no placebo control for that group. You cannot draw conclusions about muscadine’s effect on healthy adults’ metabolic markers from this study design.

The intervention used whole beverage forms — 150 mL of juice, wine, or dealcoholized wine per day. This is not the same as a standardized extract powder or capsule. The polyphenol dose, bioavailability, and matrix context of a beverage differ from those of an encapsulated ingredient. Extrapolating these findings to a capsule product requires additional research.

28 days is a short intervention window. These findings are a signal worth taking seriously, not a conclusion about long-term metabolic outcomes.

This was not a randomized, blinded, placebo-controlled trial — the design most likely to produce generalizable results. The findings are meaningful and peer-reviewed, but the study design has limitations that should inform how confidently you cite it.

Why This Still Matters for Formulators

Here’s why it still matters.

Many metabolic health ingredients have limited or no peer-reviewed human research. Their evidence base often rests on mechanistic rationale — in vitro studies showing that a compound interacts with a relevant pathway in cell culture, which is a long way from a human outcome. The Banini study, with its clearly stated limitations, still places muscadine in a category most competing ingredients cannot enter.

This research also holds up when a retailer or practitioner asks the right question — not “what does your marketing say?” but “what does your best published human study actually show?” We can answer that with a citation, a methodology, and an honest account of what was and wasn’t found. That’s a more defensible position than most suppliers in this category can offer.

The Right Application

Given what this study used, the MPC ingredient form most directly relevant to this research context is Muscadine Juice Concentrate — the beverage-form polyphenol delivery that most closely mirrors what was studied. It is appropriate for liquid supplement applications and functional beverage formulations.

Muscadine Skin/Seed Powder — our encapsulated ingredient form — provides the same phytochemical profile in capsule or tablet applications. It is a non-soluble powder, appropriate for encapsulation, not for beverage blending. The phytochemical case for that form is strong; the direct clinical link to the Banini study is more attenuated, and we will not overstate it.

If your R&D team wants to review the full Banini citation, methodology, and published abstract, contact us and we’ll send them directly. We’d rather put the actual study in front of your team than a polished summary.

Next Week

The series moves to June’s theme: Skin Health / Beauty From Within. We’ll cover Muscadine Seed Oil and Skin Extract — two ingredients with a genuinely differentiated story for cosmetic formulators and ingestible beauty brands. If you want to be ready for that conversation, visit muscadineproducts.com to request a sample or technical documentation.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Research references are cited for informational and educational purposes. The Banini study was conducted in a Type 2 diabetic population using whole beverage forms of muscadine; findings should not be generalized to healthy populations or encapsulated ingredient forms without additional research. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products.   Muscadine Products Corporation  •  Wray, Georgia  •  muscadineproducts.com